A double blinded randomised placebo controlled trial of the exelon patch (transdermal rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients.

Trial Profile

A double blinded randomised placebo controlled trial of the exelon patch (transdermal rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Delirium
  • Focus Therapeutic Use
  • Acronyms EPFD1
  • Most Recent Events

    • 11 May 2015 Status changed from not yet recruiting to discontinued as per Australian New Zealand Clinical Trials Registry.
    • 27 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top